Clinical Trial Update: Open Label Safety Study of a Birch Pollen Allergen Extract [Phase 2]

View source ↗

Summary

Open-label safety study of a birch pollen allergen extract in rhinoconjunctivitis has completed Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinoconjunctivitis

Drugs mentioned

• Birch Pollen Allergen Extract (birch pollen allergen extract)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Rhinoconjunctivitis | Phase 2 | Status: COMPLETED